Monday, October 19, 2009


Ayurveda experts and modern medicine

Ayurveda experts from across India met at Nagpur's Baidyanath Bhavan this week. Rajesh Shukla, a retired medical officer from Sagar, strongly believes that medicinal plants should be preserved and grown in their natural environment without using any chemicals like fertilisers. This prevents the plant from absorbing any heavy metals. Govind Asati, a teacher at government Ayurved College in city, holds the Ayurvedic practitioners and researchers responsible for the delay in required recognition to Ayurveda as a national system of medicine. "We have failed to take this science to even our own people in the right way," he says.
Snehlata Shrivastav
Brahmanand Nayak, an MD in Ayurveda from Bangalore, has been bringing out a research journal, first and only one of its kind published from 12 countries simultaneously. "Medicine is a science and so is Ayurveda. But we have not been able to share this fact with the world. Though research in Ayurveda may be in infancy stage, evidence is fast pouring in on how the plant-based medicines work at molecular levels.

B P Tamrakar, a professor of Ayurveda from Bhilai, says, "Ayurveda can cure sickle cell to about 90%, turn hepatitis B and E positive patients to negative and prolong the duration between blood transfusions required by a thalassemia patient. But this is possible with right integration of modern medicine with Ayurveda." He has treated 150 sickle cell patients, 70 hepatitis infections and is conducting research with the All India Institute of Medical Sciences and College of Pharmacy, Delhi.

Friday, October 02, 2009


Biocon insulin pill

The world's first oral insulin pills will hit the markets in 2011, after human clinical trials reached their final stages, says Biocon Managing Director Kiran Mazumdar-Shaw. "This is a product that we see to be a game-changer," Mazumdar-Shaw, 53, said. "It has huge potential and certainly can be a multibillion dollar blockbuster."
Of the estimated 246 million people affected by diabetes worldwide, about 5 percent to 10 percent have the type 1 form that’s marked by the inability to produce insulin, a hormone that turns blood sugar into energy, according to the International Diabetes Federation. India is the worst-affected by diabetes, with about 41 million sufferers, followed by China and the U.S.

Biocon has also purchased IDL Speciality Chemicals, which makes Active Pharmaceuticals Ingredients (API), the basic raw material used in the manufacturing of medicines. Biocon has bought IDL from Gulf Oil Corporation, a Hinduja Group company.

This page is powered by Blogger. Isn't yours?